| Catalog No. | HX243016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | IL-5R subunit alpha, IL-5 receptor subunit alpha, IL5RA, IL-5RA, IL-5R-alpha, Interleukin-5 receptor subunit alpha, CDw125, CD125, IL5R |
|---|
| Concentration | 1.17mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q01344 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -596°C. |
|---|
| Alternate Names | BIW-8405,KHK4563,MEDI-563,CAS:1044511-01-4 |
|---|
| Background | Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
